4-Hydrazinobenzene-1-sulfonamide hydrochloride | CAS:17852-52-7

We serve 4-Hydrazinobenzene-1-sulfonamide hydrochloride CAS:17852-52-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Hydrazinobenzene-1-sulfonamide hydrochloride

Chemical Name:4-Hydrazinobenzene-1-sulfonamide hydrochloride
CAS.NO:17852-52-7
Synonyms:4-Hydrazinobenzene-1-sulfonamide hydrochloride
4-Aminosulfonylphenylhydrazine hydrochloride
p-(aminosulfonyl)phenylhydrazine hydrochloride
p-sulfoamidophenylhydrazine hydrochloride
 
Physical and Chemical Properties:
Boiling Point 434.7ºC at 760 mmHg
Melting Point 217-219 ºC
Molecular Formula C6H10ClN3O2S
Molecular Weight 223.680
Flash Point 216.7ºC
 
Specification:
Appearance:Light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Celecoxib(CAS:169590-42-5).



Contact us for information like 4-Hydrazinobenzene-1-sulfonamide hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-sulfoamidophenylhydrazine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Aminosulfonylphenylhydrazine hydrochloride Use and application,4-Aminosulfonylphenylhydrazine hydrochloride technical grade,usp/ep/jp grade.


Related News: What are the symptoms? Coronavirus symptoms can look like the flu — fever, cough, trouble breathing. If you show these symptoms and recently went to China, or have been in contact with someone who visited, experts advise going to the doctor.ethyl 4-methoxy-3-oxobutanoate manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?2-Ethylaniline supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?3-Methylbut-2-enoyl chloride vendor The Philippines, the United States and Australia have expanded travel restrictions, temporarily barring noncitizens who have recently traveled to China.When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant.